Meditope Biosciences, Inc.
Oncology therapeutics based on novel molecular platform technology
- Sector
- Biotech
- Headquarters
- PASADENA, CA
- Founded
- 2011
- Latest Form D
- $1.6M, Oct 2015
- Total capital
- $3.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $3.7M
- 2 Form D · last Oct 2015
- 133 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 6 pending · first 2022
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$1.6M
- Private capital raisedForm D · SEC · 1st filing$2.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- George PrendergastDirectorNamed in SEC Form D filings
- Heng Wei ChangDirectorNamed in SEC Form D filings
- Michael GoldbergDirectorNamed in SEC Form D filings
- Robert McKenzieDirectorNamed in SEC Form D filings
- Rob KramerDirectorNamed in SEC Form D filings
- Stephanie HsiehExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 7- GrantedSelf-crosslinking AntibodiesUSPTOUS 11,459,397
- PendingAnti-egfr Antibody Drug ConjugateUSPTOApplication 16074763
- PendingSelf-crosslinking AntibodiesUSPTOApplication 62317342
Show all 7 patent records
- Self-crosslinking AntibodiesOct 4, 2022 · US 11,459,397Granted
- Anti-egfr Antibody Drug ConjugateApr 18, 2019 · Application 16074763Pending
- Self-crosslinking AntibodiesApplication 62317342Pending
- Anti-egfr Antibody Drug ConjugateApplication 62290382Pending
- Self-crosslinking AntibodiesApplication 62276803Pending
- Self-crosslinking AntibodiesApplication PCTUS2017012754Pending
- Anti-egfr Antibody Drug ConjugateApplication PCTUS2017016264Pending
Related companies, and why
- EpigenCare Inc.Similar federal contract value in Biotech · null in contracts
- Goldenrod Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Okyanos Holdings Co LLCSimilar federal contract value in Biotech · null in contracts
- Providence Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Gene Sciences, Inc.Similar federal contract value in Biotech · null in contracts
- Appili Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .